Nathan John Robison

Nathan John Robison, MD is an Associate Professor of Clinical Pediatrics at the Keck School of Medicine, University of Southern California, and attending physician in the Pediatric Neuro-Oncology Program at Children's Hospital Los Angeles. His career includes fellowships at Children’s Hospital Los Angeles, Dana-Farber/Children’s Hospital Cancer Center (Boston), and Harvard Medical School (2010–2013).

His research focuses on developing clinical trials for pediatric brain tumors, with specialties in molecular targeted therapies for low-grade glioma, diffuse pontine glioma, medulloblastoma, and neurofibromatosis. He investigates tumor microenvironment treatments like antiangiogenic and immunomodulatory strategies, and leads trials evaluating MEK inhibitors for NF1-associated plexiform neurofibromas.

Key contributions include Phase I/II trials assessing novel agents (e.g., selumetinib, mirdametinib, panobinostat) and defining consensus standards for pediatric low-grade glioma response assessment. His work spans drug resistance mechanisms, genomic profiling (e.g., RNA-sequencing for fusion genes), and long-term outcomes analysis.

Notable publications (2021–2025) address MEK inhibitor cardiac side effects, molecular subtyping of medulloblastoma, and genomic insights into pediatric gliomas. His work emphasizes translational research bridging molecular discoveries to clinical practice in pediatric neuro-oncology.